Corticosteroids, Tocilizumab or Filgrastim Do Not Impact the Efficacy of CAR T-Cell Therapy with 4- 1BB Costimulatory Domain
Poorva Bindal(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Carolyn D. Alonso(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Elisabeth Knudsen(University of Copenhagen), Sirwoo Kim, Arielle Urman, David Sermer, Michael Leukam(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Laura E. Dodge(Beth Israel Deaconess Medical Center), Pavania Elavalakanar(Beth Israel Deaconess Medical Center), Matthew Weinstock(Beth Israel Deaconess Medical Center), Emma Logan(Beth Israel Deaconess Medical Center), Caitlin A. Trottier(Tufts University)
Cited by 0
Related Papers
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
|Blood|2016|289
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
|Journal of Immunotherapy|2011|285